Last $17.27 USD
Change Today -0.07 / -0.40%
Volume 78.4K
OSIR On Other Exchanges
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

osiris therapeutics inc (OSIR) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/15 - $17.69
52 Week Low
04/21/14 - $11.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

osiris therapeutics inc (OSIR) Related Businessweek News

No Related Businessweek News Found

osiris therapeutics inc (OSIR) Details

Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing products to treat medical conditions in wound care, orthopedic, and sports medicine markets. The company’s stem cell drug, remestemcel-L, is indicated for graft versus host disease. Its products include Grafix and Ovation for acute and chronic wounds; Cartiform, a viable cartilage mesh for cartilage repair; and OvationOS, a viable bone matrix. It markets and distributes its products directly to hospitals and clinics, as well as through a network of distributors. The company has strategic partnership with Stryker Corporation to develop viable bone matrix tissue form. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

70 Employees
Last Reported Date: 03/31/14
Founded in 1992

osiris therapeutics inc (OSIR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $366.8K
Chief Financial Officer, Treasurer and Corpor...
Total Annual Compensation: $227.3K
Compensation as of Fiscal Year 2013.

osiris therapeutics inc (OSIR) Key Developments

Osiris Therapeutics, Inc. and Howmedica Osteonics Corp., Enter into an Exclusive Service Agreement

On December 19, 2014, Osiris Therapeutics, Inc. and Howmedica Osteonics Corp., also referred to as Stryker Orthopaedics, entered into an Exclusive Service Agreement, pursuant to which Stryker will become the exclusive worldwide marketer and promoter of allograft services for Osiris' viable bone matrix allograft, previously referred to as OvationOS, together with any improvements or next generation versions thereof, for use in surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery. Stryker intends to market and promote Osiris' viable bone matrix allograft pursuant to the Agreement under the name Bio4. Osiris will be responsible for supply, manufacturing, inventory management, shipments to customers, and the associated risks, and a joint steering committee will guide strategic decisions regarding marketing and commercialization, and scientific and clinical strategy, the costs of which will be shared. The Agreement provides for an initial four year exclusive term, commencing on the date of Stryker's initial commercial sale. The term may be extended by Stryker for an additional exclusive period of four and /or non-exclusive period of two years. The Agreement also contains other terms and conditions typical in arrangements of this type, including pricing and commission terms, shipment, return and consignment terms, first refusal rights, limited early termination rights and termination fees, allocation of regulatory responsibilities, intellectual property and other representations and warranties, and indemnification. Osiris is entitled to receive an initial exclusivity fee of $5,000,000 and additional fees upon any exercise by Stryker of its right to extend the initial term, whether on an exclusive or non-exclusive basis. These additional fees are reduced on a sliding scale if Stryker meets certain revenue thresholds during the term then ending, or if revenue goals are not met as a result of Osiris not fulfilling its supply obligations.

Osiris Therapeutics, Stryker Corporation Enter Strategic Partnership to Develop Viable Bone Matrix

Osiris Therapeutics said it has entered into an exclusive, worldwide partnership with Stryker Corporation for the commercialization and development of OSIR's viable bone matrix tissue form. The agreement provides SYK with exclusive, worldwide rights to OSIR's viable bone matrix under the name BIO4. OSRI will be responsible for the manufacturing, continued research and product improvement activities while SYK will be responsible for the commercialization and marketing of BIO4. The companies also said that to demonstrate the differentiating benefits and ensure the continued success and growth of this innovative product, they will collaborate on the design and conduct of future clinical development programs.

Osiris Therapeutics of Columbia Announces Executive Appointments

Osiris Therapeutics of Columbia appointed Adrian Mollo as general counsel and Jon Hopper as chief medical officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OSIR:US $17.27 USD -0.07

OSIR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $4.20 USD -0.07
Mesoblast Ltd A$4.14 AUD 0.00
Ocata Therapeutics Inc $7.22 USD -0.03
Organovo Holdings Inc $5.92 USD -0.14
Vitrolife AB kr166.50 SEK -2.00
View Industry Companies

Industry Analysis


Industry Average

Valuation OSIR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.2x
Price/Book 7.2x
Price/Cash Flow 12.6x
TEV/Sales 11.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OSIRIS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at